PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held company developing therapies based on interleukin 12 (IL-12) as a radiation medical countermeasure and as a hematopoietic immunotherapeutic (HIT), announces that it has joined the Alliance for Biosecurity. The organization is a collaboration among pharmaceutical and biotechnology companies that are working in the public interest to improve prevention and treatment of biological threats, syndromes and diseases that present global security challenges.
Help employers find you! Check out all the jobs and post your resume.
